Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Aimmune Therapeutics, Inc. | aimt-ex312_7.htm |
| EX-31.1 - EX-31.1 - Aimmune Therapeutics, Inc. | aimt-ex311_6.htm |
| EX-10.3 - EX-10.3 - Aimmune Therapeutics, Inc. | aimt-ex103_407.htm |
| 10-Q - 10-Q - Aimmune Therapeutics, Inc. | aimt-10q_20200331.htm |
Exhibit 32.1
AIMMUNE THERAPEUTICS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aimmune Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jayson Dallas, President and Chief Executive Officer of the Company, and Eric H. Bjerkholt, Chief Financial Officer of the Company, do each hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: May 11, 2020 |
|
By: |
/s/ Jayson Dallas |
|
|
|
|
Jayson Dallas M.D. |
|
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
|
Date: May 11, 2020 |
|
By: |
/s/ Eric H. Bjerkholt |
|
|
|
|
Eric H. Bjerkholt |
|
|
|
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aimmune Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.